ASH 2022 | The possibility of combining CAR-T therapy and bispecific antibodies in the treatment of NHL
In this video, Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the role of CAR-T therapy and bispecific antibodies in the treatment of non-Hodgkin lymphoma (NHL), and further comments on the possibility of combining these agents to treat patients. Dr Sureda explains that while there is no clear answer for this yet, several trials are underway investigating the sequencing of these therapies. To conclude, Dr Sureda discusses the value of bispecific antibodies as a therapeutic option for patients who fail CAR-T therapy, and the need to further investigate the potential use of bispecifics as a bridge to CAR-T. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.
